Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial

Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study

(2019) Noémie Kraaijpoel et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience

(2019) Shyam K. Poudel et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Enoxaparin 40mg per day is Inadequate for Venous Thromboembolism Prophylaxis After Thoracic Surgery

(2018) Christopher J. Pannucci et al.   ANNALS OF THORACIC SURGERY

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

(2018) Annie M. Young et al.   JOURNAL OF CLINICAL ONCOLOGY

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

(2018) Gary E. Raskob et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study

(2018) Rocío Figueroa et al.   PLoS One

Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial

(2018) C. Gibson et al.   THROMBOSIS AND HAEMOSTASIS

Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study

(2017) J.-P. Galanaud et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia

(2016) H. Sibai et al.   Current Oncology

Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients

(2016) T. van der Hulle et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

(2016) Alexander T. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Prophylactic Low–Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial

(2015) Uwe Pelzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Lack of Evidence to Support Thromboprophylaxis in Hospitalized Medical Patients with Cancer

(2013) Marc Carrier et al.   AMERICAN JOURNAL OF MEDICINE

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

(2013) Gary H. Lyman et al.   JOURNAL OF CLINICAL ONCOLOGY

Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients

(2013) Alexander T. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Practices to prevent venous thromboembolism: a brief review

(2013) Brandyn D Lau et al.   BMJ Quality & Safety

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer

(2011) A. Maraveyas et al.   EUROPEAN JOURNAL OF CANCER

Risk of Recurrent Venous Thromboembolism and Mortality in Patients With Cancer Incidentally Diagnosed With Pulmonary Embolism: A Comparison With Symptomatic Patients

(2011) Paul L. den Exter et al.   JOURNAL OF CLINICAL ONCOLOGY

A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score

(2010) S. BARBAR et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Temporal Trends in Rates of Patient Harm Resulting from Medical Care

(2010) Christopher P. Landrigan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of venous thromboembolism in cancer patients: ESMO Clinical Recommendations

(2008) M. Mandala et al.   ANNALS OF ONCOLOGY

Development and validation of a predictive model for chemotherapy-associated thrombosis

(2008) A. A. Khorana et al.   BLOOD